Das Medizinportal     Aktuelles für medizinische Fachkreise

Das Medizinportal     Aktuelles für medizinische Fachkreise




Aktuelle Therapiekonzepte in der Behandlung der Akuten Myeloischen Leukämie (AML) (S. 39–46)

Maximilian A. Röhnert, Christoph Röllig

  1. Röllig C, Beelen D, Braess J et al. Onkopedia Leitlinien – Akute Myeloische Leukämien (AML). Onkopedia 2018; www.onkopedia.com/de/onkopedia/guidelines/akute-myeloische-leukaemie-aml
  2. Juliusson G, Antunovic P, Derolf A et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009; 113: 4179 – 4187
  3. Hellenbrecht A, Messerer D, Gökbuget N. Häufigkeit von Leukämien bei Erwachsenen in Deutschland. Kompetenznetzwerk Leukämien 2008; 29-7-2011
  4. Southam C, Craver, L, Dargeon H, Burchenal J. A study of the natural history of acute leukemia with special reference to the duration of the disease and the occurrence of remissions. Cancer 1951; 4: 39–59
  5. Cornelissen J, Gratwohl A, Schlenk R et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol 2012; 9: 579–590
  6. Grimwade D, Walker H, Harrison G et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1312–1320
  7. Papaemmanuil E, Gerstung M, Bullinger L et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. New Engl J Med 2016; 374: 2209–2221
  8. Dohner H, Estey E, Grimwalde D et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017; 129: 424–447
  9. Terwijn M, van Putten W, Kelder A et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol 2013; 31: 3889–3897
  10. Freeman S, Hills R, Virgo P et al. Measurable Residual Disease at Induction Redifines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk without NPM1 Mutations. J Clin Oncol 2018; 36: 1486–1497
  11. Atallah E, Cortes J, O’Brien S et al. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood 2007; 110: 3547–3551
  12. Rollig C, Thiede C, Gramatzki M et al. A novel prognostic model in elderly patients with acute myeloid leukemia – results of 909 patients entered into the prospective AML96 trial. Blood 2010; 116: 971–978
  13. Juliusson G, Lazarevic V, Horstedt A et al. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood 2012; 119: 3890–3899
  14. Juliusson G, Antunovic P, Derolf A et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009; 113: 4179–4187
  15. Stone R, Mandrekar S, Sanford B et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. New Engl J Med 2017; 377: 454–464
  16. Castaigne S, Pautas C, Terré C et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012; 379: 1508–1516
  17. Mandelli F, Vignetti M, Suciu S et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: The EORTC and GIMEMA groups study AML-10. J Clin Oncol 2009; 27: 5397–5403
  18. Burnett A, Russel N, Hill r et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol 2013; 31: 3360–3368
  19. Cornelissen J, Gratwohl A, Schlenk R et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol 2012; 9: 579–590
  20. Mayer R, Davis R, Schiffer C et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. New Engl J Med 1994; 331: 896–903
  21. Schlenk R, Kayser S, Bullinger L et al. Differential impact of allelic ratio and insertion site in FLT3-ITD – positive AML with respect to allogeneic transplantation. Blood 2014; 124: 3441–3450
  22. Gale R, Green C, Allen C et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008; 111: 2776–2784
  23. Shayegi N, Kramer M, Bornhäuser M et al. The level of residual disease based on mutant NPM1 is an indepent prognostic factor for relapse and survival in AML. Blood 2013; 122: 83–92
  24. Krönke J, Schlenk R, Jensen K et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol 2011; 29: 2709–2716
  25. Krug U, Rollig C, Koschmieder A et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: A web-based application for prediction of outcomes. Lancet 2010; 376: 2000–2008
  26. Burnett A, Milligan D, Prentice A et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not consideres fit for intensive treatment. Cancer 2007; 109:1114–1124
  27. Kantarjian H, Thomas X, Dmoszynska A et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012; 30: 2670–2677
  28. Dombret H, Seymour J, Butrym A et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 2015; 126: 291–299
  29. Pleyer L, Burgstaller S, Girschikofsky M et al. Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. Ann Hematol 2014; 93: 1825–1838
  30. Megías-Vericat J, Martínez-Cuadrón D, Sanz M, Montesinos P. Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review. Ann Hematol 2018; 97: 1115–1153
  31. Schmid C, Labopin M, Nagler A et al. Treatment , risk factors , and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood 2012; 119: 1599–1606
  32. Hills R, Castaigne S, Appelbaum F et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 2014; 15: 986–996
  33. Lancet J, Uy G, Cortes J et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol 2018; 26: 2684–2692
  34. XOSPATA® (gilteritinib) tablets, Highlights of prescription information, FDA 2018; www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf
  35. Levis M, Perl A, Altman J et al. Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Treatment with Gilteritinib in Patients with Relapsesd/Refractory (R/R) Acute Myeloid Leukemia (AML) with FLT3 Mutations. Blood 2018; 132: 1458
  36. Cortes J, Khaled S, Martinelli G et al. Quizartinib significantly prolongs overall survival in patients with FLT3-internal tandem duplication-mutated (MUT) relapsed/refractory AML in the phase 3, randomized, controlled Quantum-R trial. EHA 2018; 218882
  37. Stein E, DiNardo C, Pollyea D et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 2017; 130: 722–731
  38. DiNardo C, Stein E, de Botton S et al. Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AML. New Engl J Med 2018; 378: 2386–2398
  39. DiNardo C, Pratz K, Pullarkat V et al. Venetoclax combined with decitabine or azacitidine in treatment-native, elderly patients with acute myeloid leukemia. Blood 2018; [Epub ahead of print]
  40. Wei A, Strickland S, Hou J et al. Venetoclax with Low-Dose Cytarabine Induces Rapid, Deep, and Durable Responses in Prevousily Untreated Older Adults with AML Ineligible for Intensive Chemotherapy. ASH 2018; Posterabstract
  41. Cortes J, Heidel F, Heuser M et al. A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF-04449913) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome. Blood 2016; 128: 99
  42. Baumeister S, Murad J, Werner L et al. Phase 1 Trial auf Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. Cancer Immunol Res. 2018; [Epub ahead of print]
  43. Stahl M, Lu B, Kim T, Zeidan A. Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock? Targeted Oncology 2017; 12: 413–447



Lokal fortgeschrittenes oder metastasiertes NSCLC: Signifikanter und anhaltender Überlebensvorteil mit Checkpoint-Inhibitor Tecentriq (S. 50–51)

  1. S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. Langversion 1.0 – Februar 2018. AWMF-Registernummer: 020/007OL
  2. Fachinformation Tecentriq, Stand Juli 2018
  3. Rittmeyer A et al. Lancet 2017; 389: 255−265
  4. Satouchi M et al. IASLC 18th WCLC, Yokohama/Japan, Abstract OA17.07
  5. Fachinformation Keytruda®, Stand: September 2018
  6. Borghaei H et al. N Engl J Med 2015; 373 (Suppl Appendix): 1627−1639
  7. Gadgeel SM et al. J Thorac Oncol 2017; 12 (Suppl 1); WCLC 2016: Abstract PL04a.02
  8. Barlesi F et al. ESMO 2016; Abstract LBA44
  9. Chen DS et al. Immunity 2013; 39(1): 1−10
  10. Chen DS et al. Cancer J 2018; 24(4): 193−204
  11. Hedge PS et al. Clin Cancer Res 2016; 22(8): 1865−1874
  12. Kim JM et al. Ann Oncol 2016; 27(8): 1492−1504
  13. Atkins MB et al. ASCO 2017; (Oral Abstract Session): Abstract 4505
  14. McDermott DF et al. J Clin Oncol 2016; 34(8): 833−842